450 international health innovation finance players will gather in Paris on June 24th and 25th 2019 for the HealthTech Investor Days (HTID®)

The first edition of HTID® draws attention from international investors, pharmaceutical companies and the European health innovation ecosystem

HTID® positions itself as a "growth accelerator" for future European HealthTech unicorns

Future medicine and financing challenges will be addressed through 10 thematic conferences

Paris (France), May 24th, 2019 – The first edition of HealthTech Investor Days (HTID®), under the high patronage of the President of the French Republic, Mr. Emmanuel MACRON, will gather the most promising European HealthTech companies (Biotech, Medtech, Digital Health and Artificial Intelligence), major pharmas and international investment funds on June 24-25th, 2019 in Paris (France).

"HTID® is a unique European platform for discussions between innovative HealthTech companies, international financial organizations and major healthcare companies. Its objective is to foster synergy and promote collaborations between all these players, and to accelerate the marketing of new medicines and therapeutic solutions," explains Maryvonne Hiance, Chairman of France Biotech, which is a French nonprofit organization and the event’s creator

HTID®’s goal is to highlight Europe’s most mature health innovation companies looking to finance their final development stages. "Europe has a multitude of innovative healthcare companies and technologies. HTID®, organized by France Biotech, will be an opportunity for us to gather international investors, pharmaceutical and industrial partners as well as the entire health tech ecosystem in the same place," says Jean-Manuel Fontaine, VP External and Scientific Affairs at Mithra Pharmaceuticals.

For two days, HTID® will combine one-on-one meetings and plenary sessions about health innovation, and its key trends and drivers. Almost 450 international experts will attend these meetings:

- Top management from approximately 90 HealthTech companies, selected for their maturity (advanced clinical trials or successful first rounds of funding).
Although registration is still open, nine countries are already represented including Belgium (Mithra Pharmaceuticals, Celyad and Sequana Medical), France (Genfit, Nanobiotix and Pixium Vision), Germany (Curevac, Heidelberg Pharma and Hepa Wash Gmbh), Sweden (Isofol Medical) and the UK (Stilla Technologies).
- **Top management of some 15 major healthcare companies** including Amgen (USA), Boehringer Ingelheim (Germany), Guerbet (France), Ipsen (France), Mediolanum (Italy), Menarini (Italy), Medtronic (USA), Pfizer (USA), Sanofi (France), Servier (France), Takeda (Japan) and Thea Pharma (France).

- **About 50 international investors already enrolled in the HTID®.**
  This first round of participants is highly diversified (international banks, insurance companies, investment banks, fund managers, private equity firms, etc.) and covers many countries (China, Dubai, Spain, USA, etc.).

- **Around 50 international experts and speakers at the ten HTID® conferences.**
  Among them, French and European ecosystem key players in health innovation (EuropaBio, EITHEALTH, LEEM, EIB, etc.), academic researchers (University of Chicago, Harvard Medical School, Paris Descartes University, etc.) and managers of major financial and stock exchange institutions (Société Générale, BNP Paribas, Euronext, Nasdaq, etc.).

**International Access:** A live broadcast and a direct live stream will be available during the event for companies from the Peninsula Hotel Business Center (Paris, France) to Business France (New-York, USA). A direct live stream from Shanghai (China) will also be available for investors.

**Find the plenary conferences program on HTID® website:** [www.htid-paris.com](http://www.htid-paris.com)

---

**About France Biotech**
Created in 1997, France Biotech is a French nonprofit organization that brings together the country's leading innovative health companies and their expert partners (investors, lawyers, research institutes, clusters, etc.). Its core mission is to promote health innovation in France and help the sector’s start-up companies and SMEs to become successful organizations, capable of rapidly developing new therapeutic solutions. France Biotech is chaired by Maryvonne Hiance and has two hundred members. [www.france-biotech.fr](http://www.france-biotech.fr)

**Press contacts**

**ALIZE RP - Europe**
Caroline Carmagnol / Tatiana Vieira  
[francebiotech@alizerp.com](mailto:francebiotech@alizerp.com)  
+336 64 18 99 59 / +336 47 38 90 04 / +336 31 13 76 20

**France Biotech**  
Maryvonne Hiance  
Chairman  
[mhiance@france-biotech.org](mailto:mhiance@france-biotech.org)

**RooneyPartners LLC – North America**
Marion Janic / Kate Barrette  
[mjanic@rooneyco.com](mailto:mjanic@rooneyco.com) / [kbarrette@rooneyco.com](mailto:kbarrette@rooneyco.com)  
+1.212.223.4017 / +1.212.223.0561

For more information on **HTID®**, contact Sophie Villedieu ([sophie.villedieu@france-biotech.org](mailto:sophie.villedieu@france-biotech.org)) and Nathalie Donne ([nathalie.donne@shapenlink.com](mailto:nathalie.donne@shapenlink.com))
Our partners:

Super Gold:

AMGEN
Bryan, Garnier & Co
Rothschild & Co

Silver:

BDC
bpifrance
Dechert LLP

Bronze:

Euronext

Our organizational supporters:

Alizé
medican
Rooney Partners
SternIR

Our supporters:

ebe noreve BioValley
EUBP Cancer Bio-Summit
The University of Chicago

EuroBio
France Invest
FrenchWeb.fr
HealthCare Drinks

Massachusetts General Hospital
ODDO BHF
Portzamparc Biopharmaceuticals
Société Générale